TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

28.19 Marcus R. New information about pediatric foodborne infections: the view from FoodNet. Curr Opin Pediatr 2008;20:79-84. 28.20 Kirk MD et al. Gastroenteritis and food-borne disease in elderly people living in long-term care. Clin Infect Dis 2010;50:397-404. 28.21 Oliver SP et al. Foodborne pathogens in milk and the dairy farm environment: food safety and public health implications. Foodborne Pathog Dis 2005;2:115-29. 28.22 Stenfors Arnesen PL et al. From soil to gut: Bacillus cereus and its food poisoning toxins. FEMS Microbiol Rev 2008;32:579-606. 28.23 Panos GZ et al. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther 2006;24:731-42. 28.24 Orth D et al. Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection. Expert Rev Anti Infect Ther 2008;6:101-8. 28.25 Karch H et al. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005; 295:405-18. 28.26 Mainil JG et al. Verotoxigenic Escherichia coli from animals, humans and foods: who‘s who? J Appl Microbiol 2005;98:1332-44. 28.27 Tarr PI et al. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073-86. 28.28 Karmali MA et al. Verocytotoxin-producing Escherichia coli (VTEC). Vet Microbiol 2010;140:360-70. 28.29 Hammerum AM et al. Human health hazards from antimicrobial-resistant Escherichia coli of animal origin. Clin Infect Dis 2009;48:916-21. 28.30 Welinder-Olsson C et al. Enterohemorrhagic Escherichia coli (EHEC). Scand J Infect Dis 2005;37: 405-16. 28.31 Kluytmans JA. Methicillin-resistant Staphylococcus aureus in food – innocent bystander or serious threat? Clin Microbiol Infect 2010;16:11-5. 28.32 Murray RJ. Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern Med J 2005;35(suppl. 2):S106-19. 29A.1 Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14. 29A.2 Bouza E et al. Fever of unknown origin in solid organ transplant recipients. Infect Dis Clin North Am 2007;21:1033-54. 29A.3 Martín-Dávila M et al. Transmission of tropical and geographically restricted infections during solidorgan transplantation. Clin Microbiol Rev 2008;21:60-96. 29B.1 Cadena J et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009;9:2085-91. 29B.2 Husain S et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006;8:213-8. 29B.3 Drew RH et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung transplant recipients. Transplantation 2004;77:232-7. 29B.4 Lowry CM et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007;9:121-5. 29B.5 Ullmann AJ et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347. 29B.6 Ben-Ami R et al. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr Opin Infect Dis 2009;22:376-84. 29B.7 Allinson K et al. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008;61:734-42. 29B.8 Winston DJ et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Ann Intern Med 2003;138:705-13. 29B.9 Strasfeld L et al. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006;4:457-68. 29B.10 Narimatsu H et al. Management of fungal infections following allogeneic stem cell transplantation. Expert Rev Anti Infect Ther 2008;6:373-84. 29B.11 Marr KA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33. 29B.12 Husain S et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case controlled study. Transplantation 2003;75:2023-9. 29B.13 Cruciani M et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006;12:850-8. 29B.14 Marr KA. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Curr Opin Infect Dis 2008;21:409-14. 29B.15 Marr KA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33. 29B.16 Strasfeld L et al. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006;4:457-68. 29B.17 Narimatsu H et al. Management of fungal infections following allogeneic stem cell transplantation. Expert Rev Anti Infect Ther 2008;6:373-84. 29B.18 Winston DJ et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Ann Intern Med 2003;138:705-13. 29B.19 Legendre C et al. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis 2008;46:732-40. 29B.20 Singh N. Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients. Clin Infect Dis 2008;47:296-7. 29B.21 Arthurs SK et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and
mortality after kidney transplantation. Clin Infect Dis 2008;46:840-6. 29B.22 Torres-Madriz G et al. Perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2008;47:702-11. 29B.23 Griffiths P et al. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF Workshop, 2007. Herpes 2008;15:4-12. 29B.24 Hodson EM et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005;365: 2105-15. 29B.25 Kalil AC et al. Meta-Analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-80. 29B.26 Preiksaitis JK et al. Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Ogan Transplantation. Final report. Am J Transplant 2005;5:218-27. 29B.27 Singh N. Late onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005; 40:704-8. 29B.28 Snydman DR. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis 2005;40:709-12. 29B.29 Mwintshi K et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Expert Rev Anti Infect Ther 2007;5:295-304. 29B.30 Small LN et al. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006:43:869-80. 29B.31 Meylan PR et al. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know. Clin Infect Dis 2006;43:881-3. 29B.32 Legendre C et al. Improving outcomes for solid-organ transplant recipients at risk from cyto-megalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis 2008;46:732-40. 29B.33 van der Heiden PL et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006;37:693-8. 29B.34 Ayala E et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37:851-6. 29B.35 Allice T et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother 2009;63:600-8. 29B.36 Busca A et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stemcell transplantation. Transpl Infect Dis 2007;9:102-7. 29B.37 Strasfeld L et al. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006;4:457-68. 29B.38 Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002;35:999-1004. 29B.39 Meijer E et al. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003;16:647-57. 29B.40 Li F et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007;45:439-47. 29B.41 Avery RK. Ganciclovir-resistant cytomegalovirus disease in heart transplant recipients: the dilemma of donor-positive/recipient-negative serostatus. Clin Infect Dis 2007;45:448-9. 29B.42 Levitsky J et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008;8:158-61. 29B.43 Egli A et al. Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review of the literature. Transpl Infect Dis 2008;10:27-43. 29B.44 Singh N et al. Efficacy of valganciclovir administered as pre-emptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late onset cytomegalovirus disease. Transplantation 2005;79:85-90. 29B.45 Singh N et al. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae and mortality) in liver transplant recipients with the use of pre-emptive therapy for 13 years. Transplantation 2005;79:1428-34. 29B.46 Zamora MR et al. Management of cytomegalovirus infection in lung transplant recipients: evidence based recommendations. Transplantation 2005;80:157-63. 29B.47 Perrillo RP et al. A Multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-32. 29B.48 Naoumov NV et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-94. 29B.49 Coffin CS et al. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007;14 (suppl. 1):37-44. 29B.50 Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004;24 (suppl. 1):55-62. 29B.51 Gasink LB et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. J Am Med Assoc 2006;296:1843-50. 29B.52 Biggins SW et al. Management of recurrent hepatitis C in liver transplant recipients. Infect Dis Clin North Am 2006;20:155-74. 29B.53 Miller GG et al. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant 2007;7:741-7. 29B.54 Erard V et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 196:266-70. 29B.55 Erard V et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 193:266-70.
Page 1 and 2:
TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4:
1.89 Laupland KB. Vascular and para
Page 5 and 6:
of NICE guidance. Br Med J 2008;337
Page 7 and 8:
tions à Clostridium difficile dans
Page 9 and 10:
sis of placebo-controlled trials. C
Page 11 and 12:
1.446 Centers for Disease Control a
Page 13 and 14:
1.532 Olaison L et al. Enterococcal
Page 15 and 16:
1.615 Muder RR et al. Isolation of
Page 17 and 18:
2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20:
2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22:
1.873 Korting HC et al. Current top
Page 23 and 24:
1.970 Thomas RJ et al. Current mana
Page 25 and 26:
of severe respiratory failure. Clin
Page 27 and 28:
1.1166 Aldape MJ et al. Clostridium
Page 29 and 30:
2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32:
test methodology. Eur J Clin Microb
Page 33 and 34:
2B.39 Cookson BD et al. Guidelines
Page 35 and 36:
2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38:
82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40:
after acute pyelonephritis: a multi
Page 41 and 42:
for intensive care patients with no
Page 43 and 44:
among hospitalized patients. Clin I
Page 45 and 46:
Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97: product characteristics. Available
Page 101 and 102: 33A.1 Kearney BP et al. The penetra
Page 103 and 104: Clin Plast Surg Clinics in Plastic
Page 105 and 106: Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?